Pharmacy Drugs
Recent Posts
- Malignant Brain Tumors: Chemotherapy Alone Is Just As Effective As Radiation / New Positive Prognostic Factor Found
- Positive Interim Data From Minnow Medical Peripheral Artery Disease Trial Presented At TCT 2009 Conference
- Intercept Pharmaceuticals’ FXR Agonist INT-747 Meets Primary Endpoint In A Phase II Clinical Trial In Type 2 Diabetic Patients
- Largest Clinical Trial To Test Benefits Of Aspirin In Australia
- University Of Florida To Receive $29.5 Million In Recovery Act Funds To Begin Study Of Whether Exercise Prevents Disability In Older Adults
Random Posts
- 5-Year Study Published In Diabetologia Demonstrated Long-Term Safety Of Lantus(R) Compared To NPH
- Synexus Leads The Way In South Africa With Vital Paediatric Vaccines Trial
- Society Welcomes 'Yes' Vote To Charter Changes
- Baxter, FDA Say Heparin Not Responsible for Delaware Deaths
- Barrett's Esophagus Patients Have Same Survival Rates As General Population, Says New Mayo Clinic Study
- Husband's Studies Lead To Clinical Trial - Multiple Sclerosis Society
- Karo Bio Announces That Merck & Co., Inc. Plans To Proceed With Phase II Clinical Evaluation Of Candidate Compound
- GenSpera Receives Approval To Commence G-202 Phase I Trial At The University Of Wisconsin Carbone Cancer Center
- Study Demonstrated Once-Daily Vyvanse® CII Provided Significant Improvement Of ADHD Symptoms For Children At 13 Hours After Administration
- PAC09 Excellence And Pharmacy Student Of The Year Awards, Australia
BioElectronics Announces Pivotal Clinical Study On Musculoskeletal Disorders
Posted by: admin in Pharmacy Drugs on September 22nd, 2009
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced its sponsorship of a groundbreaking clinical study on musculoskeletal disorders. The randomized, double blinded and placebo-controlled study will be supervised by a primary investigator, Sheena Kong, MD of San Francisco, California in conjunction with several other leading physicians.
“This is a very exciting field of research and we are looking forward to determining the safety and efficacy of BioElectronics Corporation’s ActiPatch for the treatment of many different types of musculoskeletal complaints,” commented Dr. Kong. “Since my days studying at Harvard University I have been very interested in treatments such as Pulsed Electromagnetic Field therapy (PEMF) as an alternative to pharmaceuticals. We are currently in process of working with our Independent Review Board (IRB) and registering the study with the National Institutes of Health (NIH). Patient recruitment is expected to begin over the next few weeks. We believe this will be one of the largest studies ever completed on the subject of general muscular skeletal complaints.”
Andrew Whelan, CEO of BioElectronics Corp., added, “The sponsorship and completion of the study are significant events for our Company. While we are seeing success within the plastic surgery market and in our international distribution channels, we believe the U.S. markets for back, knee, foot/ankle, and elbow pain are our biggest opportunities. This study is specifically designed to allow us to apply to the U.S. Food and Drug Administration for an indication for pain relief for general muscular skeletal complaints. With the many concerns over the dangers of taking medications such as acetaminophen and NSAIDs, we believe U.S. consumers are looking for safer and more effective pain relief options. We believe our unique and patented drug-free technologies will effectively fill this need.”
The management team of BioElectronics will hold a conference call on Thursday, June 18 at 4:15 p.m. (EDT) to discuss this study and other ongoing clinical trials several of which are nearing conclusion. On the call Barry Eppley, M.D., D.M.D will discuss the recent clinical study on dysmenorrhea and Sheena Kong, MD will discuss the design of the musculoskeletal disorder study. To access the conference call, please dial 712-432-0080 approximately 10 minutes prior to the start time and enter access code 404367# to be placed into the conference.
Source
BioElectronics Corporation
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.